ASH 2018: Dr. Furman on Limited Duration Novel Agents in CLL (chronic lymphocytic leukemia) It’s every chronic lymphocytic leukemia patient’s dream: Take some pills every day for a few years and you’re done with... March 18, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Michael Hallek on Combination Therapy and More in CLL (chronic lymphocytic leukemia) Professor Michael Hallek leads the collaborative CLL German research group from his clinic in Cologne. Among other contributions, the research... March 3, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. John Byrd, Ibrutinib and “A Second Chance at Life” By Larry Marion Dr. John Byrd, the Ohio State University professor and principal investigator of the anti-CLL drug ibrutinib during its... February 14, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. John Byrd on Acalabrutinib in CLL Over the last 8 years, Dr. John Byrd out of Ohio State in Columbus, OH helped lead the charge of... February 8, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Pagel on PI3K inhibitors in CLL (chronic lymphocytic leukemia) We all know that blocking the B cell receptor (BCR) has revolutionized the management of chronic lymphocytic leukemia. This has mostly... February 5, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Furman on the evolving role of clinical trials in CLL ASH, short for the American Society of Hematology Annual Meeting and Exposition, is the showcase for the latest and best... January 28, 20192018 ConferencesBy Brad Hedrick
ASCO 2018: Dr. Matt Davids on CLL Clinical Trials Open at Dana Farber Cancer Institute In following up on our interview about the CLL research presented at ASCO 2018, Dr. Matt Davids from Dana Farber... January 22, 20192018 ConferencesBy Brad Hedrick
ERIC 2018: Dr. Jennifer Brown on Getting the Correct Diagnosis of CLL (chronic lymphocytic leukemia) The European Research Initiative on CLL (ERIC) held their first international meeting, NEW FRONTIERS IN CLL RESEARCH, in Barcelona, Spain Oct.... January 13, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Stephan Stilgenbauer on the superiority of ibrutinib + rituximab vs FCR for frontline use in CLL (Chronic Lymphocytic Leukemia) in patients under 70 ASH (American Society of Hematology Annual Meeting) is the largest and most important forum for the presentation of new blood... January 8, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Professor Peter Hillmen on the Combination of Ibrutinib and Obinutuzumab in CLL: Timing Matters ASH (American Society of Hematology) Annual Meeting and Exposition is where nearly all the most important blood cancer research is... December 17, 20182018 ConferencesBy Brad Hedrick
